ES2358182T3 - Genes de control para la normalización de datos de análisis de la expresión génica. - Google Patents
Genes de control para la normalización de datos de análisis de la expresión génica. Download PDFInfo
- Publication number
- ES2358182T3 ES2358182T3 ES08716110T ES08716110T ES2358182T3 ES 2358182 T3 ES2358182 T3 ES 2358182T3 ES 08716110 T ES08716110 T ES 08716110T ES 08716110 T ES08716110 T ES 08716110T ES 2358182 T3 ES2358182 T3 ES 2358182T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- control
- nucleic acids
- genes
- gene expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 178
- 230000014509 gene expression Effects 0.000 title claims abstract description 96
- 238000010195 expression analysis Methods 0.000 title claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 64
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 60
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 60
- 239000000523 sample Substances 0.000 claims abstract description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 54
- 210000004369 blood Anatomy 0.000 claims abstract description 41
- 239000008280 blood Substances 0.000 claims abstract description 41
- 230000009466 transformation Effects 0.000 claims abstract description 13
- 238000000338 in vitro Methods 0.000 claims abstract description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 46
- 238000012360 testing method Methods 0.000 claims description 43
- 238000010606 normalization Methods 0.000 claims description 41
- 206010040047 Sepsis Diseases 0.000 claims description 40
- 238000002493 microarray Methods 0.000 claims description 29
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 25
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 18
- 238000009396 hybridization Methods 0.000 claims description 17
- 238000005259 measurement Methods 0.000 claims description 17
- 230000003321 amplification Effects 0.000 claims description 16
- 238000004458 analytical method Methods 0.000 claims description 16
- 108020004999 messenger RNA Proteins 0.000 claims description 15
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000013610 patient sample Substances 0.000 claims description 8
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- 108700011259 MicroRNAs Proteins 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000002679 microRNA Substances 0.000 claims description 5
- 238000003753 real-time PCR Methods 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 238000011835 investigation Methods 0.000 claims description 4
- 238000004393 prognosis Methods 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 238000013523 data management Methods 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000011049 pearl Substances 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 238000013459 approach Methods 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 238000011330 nucleic acid test Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 abstract description 3
- 238000003633 gene expression assay Methods 0.000 abstract description 2
- 102100026548 Caspase-8 Human genes 0.000 abstract 2
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 abstract 2
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 abstract 2
- 101000687642 Homo sapiens snRNA-activating protein complex subunit 1 Proteins 0.000 abstract 2
- 102100022339 Integrin alpha-L Human genes 0.000 abstract 2
- 102000003810 Interleukin-18 Human genes 0.000 abstract 2
- 108090000171 Interleukin-18 Proteins 0.000 abstract 2
- 108010015181 PPAR delta Proteins 0.000 abstract 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 abstract 2
- 102100024840 snRNA-activating protein complex subunit 1 Human genes 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 description 123
- 241000282414 Homo sapiens Species 0.000 description 109
- 210000004027 cell Anatomy 0.000 description 23
- 239000013615 primer Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 238000011002 quantification Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 10
- 210000000601 blood cell Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000013501 data transformation Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 101150066838 12 gene Proteins 0.000 description 1
- 101150082072 14 gene Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- -1 synthetic analogs Proteins 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007010252A DE102007010252B4 (de) | 2007-03-02 | 2007-03-02 | Kontrollgene zur Normalisierung von Genexpressionsanalysedaten |
| DE102007010252 | 2007-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2358182T3 true ES2358182T3 (es) | 2011-05-06 |
Family
ID=39670079
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08716110T Active ES2358182T3 (es) | 2007-03-02 | 2008-02-28 | Genes de control para la normalización de datos de análisis de la expresión génica. |
| ES10196834.5T Active ES2524643T3 (es) | 2007-03-02 | 2008-02-28 | Genes control para la normalización de datos de análisis de expresión génica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10196834.5T Active ES2524643T3 (es) | 2007-03-02 | 2008-02-28 | Genes control para la normalización de datos de análisis de expresión génica |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8338099B2 (enExample) |
| EP (2) | EP2392668B1 (enExample) |
| JP (1) | JP5430407B2 (enExample) |
| AT (1) | ATE493517T1 (enExample) |
| CA (1) | CA2679017A1 (enExample) |
| DE (2) | DE102007010252B4 (enExample) |
| ES (2) | ES2358182T3 (enExample) |
| WO (1) | WO2008107114A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060084082A1 (en) | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| DE102007036678B4 (de) | 2007-08-03 | 2015-05-21 | Sirs-Lab Gmbh | Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion |
| DE102008000715B9 (de) * | 2008-03-17 | 2013-01-17 | Sirs-Lab Gmbh | Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen |
| EP2309001A1 (de) * | 2009-09-23 | 2011-04-13 | SIRS-Lab GmbH | Verfahren zur in vitro Erfassung und Unterscheidung von pathophysiologischen Zuständen |
| US20110076685A1 (en) * | 2009-09-23 | 2011-03-31 | Sirs-Lab Gmbh | Method for in vitro detection and differentiation of pathophysiological conditions |
| DE102009044085A1 (de) * | 2009-09-23 | 2011-11-17 | Sirs-Lab Gmbh | Verfahren zur in vitro Erfassung und Unterscheidung von pathophysiologischen Zuständen |
| SI2639312T1 (sl) * | 2012-03-13 | 2017-12-29 | Siemens Healthcare Gmbh | Imunski test za detekcijo miRNA |
| BR112017009009A2 (pt) | 2014-11-26 | 2018-01-30 | Toray Industries, Inc. | método e dispositivo para corrigir um ou mais níveis de expressão, programa(s) para a correção do(s) nível(eis) de expressão de rna(s), meio de gravação legível por computador e chip para análise da expressão de rna pequeno |
| CA2986787A1 (en) | 2015-05-28 | 2016-12-01 | Immunexpress Pty Ltd | Validating biomarker measurement |
| JP7411979B2 (ja) * | 2019-07-19 | 2024-01-12 | 公立大学法人福島県立医科大学 | 内部標準遺伝子 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1190366B1 (en) * | 1999-05-25 | 2005-10-26 | Aventis Pharmaceuticals Inc. | Mathematical analysis for the estimation of changes in the level of gene expression |
| EP2366799A3 (de) * | 2003-04-02 | 2012-06-20 | SIRS-Lab GmbH | Verfahren zur in vitro Erkennung schwerer Sepsis |
| DE10336511A1 (de) * | 2003-08-08 | 2005-02-24 | Sirs-Lab Gmbh | Verfahren zur Erkennung von schwerer Sepsis |
| DE102004009952B4 (de) * | 2004-03-01 | 2011-06-01 | Sirs-Lab Gmbh | Verfahren zur Erkennung von Sepsis |
| US7587279B2 (en) * | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
| JP2006170670A (ja) * | 2004-12-13 | 2006-06-29 | Sony Corp | 遺伝子発現量規格化方法、プログラム、並びにシステム |
| US20060136145A1 (en) * | 2004-12-20 | 2006-06-22 | Kuo-Jang Kao | Universal reference standard for normalization of microarray gene expression profiling data |
-
2007
- 2007-03-02 DE DE102007010252A patent/DE102007010252B4/de not_active Expired - Fee Related
-
2008
- 2008-02-28 ES ES08716110T patent/ES2358182T3/es active Active
- 2008-02-28 AT AT08716110T patent/ATE493517T1/de active
- 2008-02-28 EP EP10196834.5A patent/EP2392668B1/de not_active Not-in-force
- 2008-02-28 ES ES10196834.5T patent/ES2524643T3/es active Active
- 2008-02-28 US US12/529,423 patent/US8338099B2/en not_active Expired - Fee Related
- 2008-02-28 CA CA002679017A patent/CA2679017A1/en not_active Abandoned
- 2008-02-28 JP JP2009551137A patent/JP5430407B2/ja not_active Expired - Fee Related
- 2008-02-28 WO PCT/EP2008/001582 patent/WO2008107114A2/de not_active Ceased
- 2008-02-28 EP EP08716110A patent/EP2118315B1/de not_active Not-in-force
- 2008-02-28 DE DE502008002136T patent/DE502008002136D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2524643T3 (es) | 2014-12-10 |
| EP2118315B1 (de) | 2010-12-29 |
| DE102007010252A8 (de) | 2008-12-11 |
| DE102007010252B4 (de) | 2013-07-04 |
| JP2010519893A (ja) | 2010-06-10 |
| US20100184608A1 (en) | 2010-07-22 |
| WO2008107114A2 (de) | 2008-09-12 |
| EP2392668B1 (de) | 2014-10-29 |
| US8338099B2 (en) | 2012-12-25 |
| CA2679017A1 (en) | 2008-09-12 |
| WO2008107114A3 (de) | 2008-11-20 |
| EP2392668A3 (de) | 2012-05-30 |
| EP2392668A2 (de) | 2011-12-07 |
| DE102007010252A1 (de) | 2008-09-04 |
| ATE493517T1 (de) | 2011-01-15 |
| EP2118315A2 (de) | 2009-11-18 |
| JP5430407B2 (ja) | 2014-02-26 |
| DE502008002136D1 (de) | 2011-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2358182T3 (es) | Genes de control para la normalización de datos de análisis de la expresión génica. | |
| US12467095B2 (en) | Salivary biomarkers of brain injury | |
| CN107267602B (zh) | 一种与男性生殖功能障碍相关的精子piRNA标志物组合及其应用 | |
| US20080026385A1 (en) | Oligonucleotides For Cancer Diagnosis | |
| CN107916289B (zh) | 精子piRNA和精子蛋白MitoPLD作为检测和预测男性不育的生物标志物 | |
| Krafft et al. | Analysis of gene expression in canine idiopathic pulmonary fibrosis | |
| CA2699433A1 (en) | Use of polynucleotides for detecting gene activities for distinguishing between local and systemic infection | |
| KR101646189B1 (ko) | 내인성 아토피 피부염 진단용 마커 및 그의 용도 | |
| ES2336928T3 (es) | Metodos de diagnostico y pronostico de esteatohepatitisno alcoholica (ehna). | |
| ES2856232B2 (es) | Biomarcadores para predecir la respuesta de un sujeto a una terapia con bcg, metodos y usos basados en los mismos | |
| WO2021060311A1 (ja) | 脳腫瘍を検査する方法 | |
| KR101808221B1 (ko) | 인지 기능 예측용 aqp4 유전자의 단일 염기 다형성을 검출하는 프라이머, 마이크로어레이, 및 키트, 및 이를 이용한 방법 | |
| RU2777663C1 (ru) | Количественный метод определения экспрессии аллелей GNAO1 здоровой формы и с мутацией c.607 G>A | |
| KR102421915B1 (ko) | Pept1의 신규한 snp 및 변이체 | |
| CN115927607B (zh) | 生物标志物在胃癌诊断中的应用 | |
| US20250298015A1 (en) | Diagnostic method of detecting inflammation biomarker(s) | |
| JP2011062161A (ja) | 血液を用いた大腸癌の診断法 | |
| HK40095431A (en) | Biomarkers of traumatic brain injury | |
| JPWO2020054474A1 (ja) | 関節リウマチを検査する方法 | |
| JP2006042701A (ja) | マイクロアレイを用いた生体活性の変化の評価方法 |